Adage Capital Partners
CLDX icon

Adage Capital Partners’s Celldex Therapeutics CLDX Stock Holding History

Adage Capital Partners’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-400,000
Closed -$10.8M – 1055
2022
Q2 		$10.8M Sell
400,000
-400,000
-50% -$11.6M 0.02% 654
2022
Q1 		$27.2M Buy
800,000
+150,000
+23% +$4.79M 0.05% 367
2021
Q4 		$25.1M Sell
650,000
-300,000
-32% -$13.1M 0.05% 396
2021
Q3 		$51.3M Sell
950,000
-868,478
-48% -$40.8M 0.1% 209
2021
Q2 		$60.8M Sell
1,818,478
-81,522
-4% -$2.24M 0.12% 180
2021
Q1 		$39.1M Sell
1,900,000
-600,000
-24% -$13.8M 0.08% 263
2020
Q4 		$43.8M Buy
2,500,000
+450,000
+22% +$8.1M 0.1% 225
2020
Q3 		$30.4M Buy
2,050,000
+300,000
+17% +$3.51M 0.08% 274
2020
Q2 		$22.8M Buy
+1,750,000
New +$7.76M 0.06% 358

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Adage Capital Partners's CLDX Position: Q3 2022 in Review

Adage Capital Partners sold out of Celldex Therapeutics (CLDX) in Q3 2022, closing a stake of 400,000 shares — an estimated $10.8M sold.

Adage Capital Partners first reported a position in CLDX in Q2 2020 and held it in 9 quarters. The position peaked at $60.8M in Q2 2021. 159 funds tracked by Wall St. Rank hold CLDX as of Q3 2022.

  • Adage Capital Partners reported no remaining Celldex Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Adage Capital Partners sold 400,000 Celldex Therapeutics shares in Q3 2022, an estimated $10.8M.
  • Adage Capital Partners first reported a position in Celldex Therapeutics in Q2 2020 and held it in 9 quarters.
  • Adage Capital Partners's Celldex Therapeutics position peaked at $60.8M in Q2 2021.
  • 159 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2022.

Based on Adage Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.